[1] 王文广,匡德宣,李娜,等.树鼩Mfsd2a基因的克隆分析和不同组织表达量的检测[J].实验动物与比较医学, 2019, 39(3):178-186. [2] BEN-ZVI A, LACOSTE B, KUR E, et al. Mfsd2a is critical for the formation and function of the blood-brain barrier[J]. Nature, 2014, 509(7501):507-511. [3] ZHAO C S, MA J W, WANG Z, et al. Mfsd2a attenuates blood-brain barrier disruption after sub-arachnoid hemorrhage by inhibiting caveolae-mediated transcellular transport in rats[J]. Transl Stroke Res,2020, 11(5):1012-1027. [4] LIANG C Y, WANG L J, CHEN C P, et al. GCM1 regulation of the expression of syncytin 2 and its cognate receptor MFSD2A in human placenta[J]. Biol Reprod, 2010, 83(3):387-395. [5] XING S, KAN J, SU A S, et al. The prognostic value of major facilitator superfamily domain-containing protein 2A in patients with hepatocellular carcinoma[J]. Aging, 2019, 11(19):8474-8483. [6] ANGERS M, ULDRY M, KONG D, et al. Mfsd2a encodes a novel major facilitator superfamily domain-containing protein highly induced in brown adipose tissue during fasting and adaptive thermogenesis[J]. Biochem J, 2008, 416(3):347-355. [7] CATER R J, CHUA G L, ERRAMILLI S K, et al. Structural basis of omega-3 fatty acid transport across the blood-brain barrier[J]. Nature, 2021, 595(7866):315-319. [8] WOOD C A P, ZHANG J R, AYDIN D, et al. Structure and mechanism of blood-brain-barrier lipid transporter MFSD2A[J]. Nature, 2021, 596(7872):444-448. [9] O'BROWN N M, MEGASON S G, GU C H. Suppression of transcytosis regulates zebrafish blood-brain barrier function[J]. eLife, 2019, 8:e47326. [10] CUI Y X, WANG Y X, SONG X P, et al. Brain endothelial PTEN/AKT/NEDD4-2/MFSD2A axis regulates blood-brain barrier permeability[J]. Cell Rep, 2021, 36(1):109327. [11] NGUYEN L N, MA D L, SHUI G H, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid[J]. Nature, 2014, 509(7501):503-506. [12] WANG Z F, ZHENG Y T, WANG F, et al. Mfsd2a and Spns2 are essential for sphingosine-1-phosphate transport in the formation and maintenance of the blood-brain barrier[J]. Sci Adv, 2020, 6(22):eaay8627. [13] WANG Z X, LIU C H, HUANG S, et al. Wnt signaling activates MFSD2A to suppress vascular endothelial transcytosis and maintain blood-retinal barrier[J]. Sci Adv, 2020, 6(35):eaba7457. [14] CHOW B W, GU C H. Gradual suppression of transcytosis governs functional blood-retinal barrier formation[J]. Neuron, 2017, 93(6):1325-1333. [15] LOBANOVA E S, SCHUHMANN K, FINKELSTEIN S, et al. Disrupted blood-retina lysophosphatidylcholine transport impairs photoreceptor health but not visual signal transduction[J]. J Neurosci, 2019, 39(49):9689-9701. [16] PRIETO-SÁNCHEZ M T, RUIZ-PALACIOS M, BLANCO-CARNERO J E, et al. Placental MFSD2a transporter is related to decreased DHA in cord blood of women with treated gestational diabetes[J]. Clin Nutr, 2017, 36(2):513-521. [17] YANG Y R, XIONG X Y, LIU J, et al. Mfsd2a (major facilitator superfamily domain containing 2a) attenuates intracerebral hemorrhageinduced blood-brain barrier disruption by inhibiting vesicular transcytosis[J]. J Am Heart Assoc, 2017, 6(7):e005811. [18] QU C H, SONG H, SHEN J, et al. Mfsd2a reverses spatial learning and memory impairment caused by chronic cerebral hypoperfusion via protection of the blood-brain barrier[J]. Front Neurosci, 2020, 14:461. [19] ESER OCAK P, OCAK U, SHERCHAN P, et al. Overexpression of Mfsd2a attenuates blood brain barrier dysfunction via Cav-1/Keap-1/Nrf-2/HO-1 pathway in a rat model of surgical brain injury[J]. Exp Neurol, 2020, 326:113203. [20] YANG J, MA K, ZHANG C P, et al. Burns impair blood-brain barrier and mesenchymal stem cells can reverse the process in mice[J]. Front Immunol, 2020, 11:578879. [21] SHANG J W, YAMASHITA T, TIAN F, et al. Chronic cerebral hypoperfusion alters amyloid-β transport related proteins in the cortical blood vessels of Alzheimer's disease model mouse[J]. Brain Res, 2019, 1723:146379. [22] WEI J P, QIN L X, FU Y, et al. Long-term consumption of alcohol exacerbates neural lesions by destroying the functional integrity of the blood-brain barrier[J]. Drug Chem Toxicol, 2022, 45(1):231-238. [23] ZHOU J, CHI X J, CHENG M, et al. Zika virus degrades the ω-3 fatty acid transporter Mfsd2a in brain microvascular endothelial cells and impairs lipid homeostasis[J]. Sci Adv, 2019, 5(10):eaax7142. [24] ZHANG C L, WANG H L, LI P C, et al. Mfsd2a overexpression alleviates vascular dysfunction in diabetic retinopathy[J]. Pharmacol Res, 2021, 171:105755. [25] POWELL T L, BARNER K, MADI L N, et al. Sex-specific responses in placental fatty acid oxidation, esterification and transfer capacity to maternal obesity[J]. Biochim Biophys Acta BBA Mol Cell Biol Lipids, 2021, 1866(3):158861. [26] SÁNCHEZ-CAMPILLO M, RUIZ-PALACIOS M, RUIZ-ALCARAZ A J, et al. Child head circumference and placental MFSD2a expression are associated to the level of MFSD2a in maternal blood during pregnancy[J]. Front Endocrinol (Lausanne), 2020, 11:38. [27] PICCIRILLO A R, HYZNY E J, BEPPU L Y, et al. The lysophosphatidylcholine transporter MFSD2A is essential for CD8+memory T cell maintenance and secondary response to infection[J]. J Immunol, 2019, 203(1):117-126. [28] UNGARO F, TACCONI C, MASSIMINO L, et al. MFSD2A promotes endothelial generation of inflammation-resolving lipid mediators and reduces colitis in mice[J]. Gastroenterology, 2017, 153(5):1363-1377. [29] SHI X, HUANG Y M, WANG H Y, et al. MFSD2A expression predicts better prognosis in gastric cancer[J]. Biochem Biophys Res Commun, 2018, 505(3):699-704. [30] TIWARY S, MORALES J E, KWIATKOWSKI S C, et al. Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a[J]. Sci Rep, 2018, 8:8267. [31] COLOMBO F, FALVELLA F S, GALVAN A, et al. A 5'-region polymorphism modulates promoter activity of the tumor suppressor gene MFSD2A[J]. Mol Cancer, 2011, 10:81. [32] HE W, JU D D, JIE Z J, et al. Aberrant CpG-methylation affects genes expression predicting survival in lung adenocarcinoma[J]. Cancer Med, 2018, 7(11):5716-5726. [33] 安松林,马玲,赵月,等.主要促进因子超家族成员MFSD2A对肝癌细胞增殖、凋亡和侵袭的影响[J].首都医科大学学报, 2021, 42(6):1000-1006. |